Monte A. Del Monte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Monte A. Del Monte has a total of 380 co-authors. Here are the top co-authors by number of shared publications:
- Steven M. Archer
University of Michigan, Kellogg Eye Center
14 shared publications - David C. Musch
Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA
4 shared publications Maya Eibschitz-Tsimhoni
4 shared publications- Maya Eibschitz-Tsimhoni
Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA
4 shared publications Piyush C. Kothary
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA
4 shared publicationsF. H. Leibach
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA, 30912-2100
3 shared publications
Latest Publications
- 1 December 2019
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 23 (6) , 363
Lateral rectus sag and recurrent esotropia in children
- 1 December 2019
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 23 (6) , 363
Lateral rectus sag and recurrent esotropia in children
- Open Access
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (11) , 1312-1316
Prevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder of lipid storage and bile acid synthesis.1 Bilateral cataracts are a clinical hallmark of CTX, reported in 76% to 88% of affected individuals.2,3 Childhood-onset bilateral cataracts are a common presentation in patients with CTX.3 Cerebrotendinous xanthomatosis–related cataracts have a characteristic morphology, presenting as diffuse flecks, seen best by retroillumination, with posterior capsular opacities.4
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (11) , 1312-1316
Open AccessPrevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder of lipid storage and bile acid synthesis.1 Bilateral cataracts are a clinical hallmark of CTX, reported in 76% to 88% of affected individuals.2,3 Childhood-onset bilateral cataracts are a common presentation in patients with CTX.3 Cerebrotendinous xanthomatosis–related cataracts have a characteristic morphology, presenting as diffuse flecks, seen best by retroillumination, with posterior capsular opacities.4
- 1 September 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (9) , 791-801
Ocular Manifestations of Cutis Marmorata Telangiectatica Congenita
- 1 September 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (9) , 791-801
Ocular Manifestations of Cutis Marmorata Telangiectatica Congenita
- 1 October 2018
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 22 (5) , 340-343
The effect of oral statin therapy on strabismus in patients with thyroid eye disease
- 1 October 2018
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 22 (5) , 340-343
The effect of oral statin therapy on strabismus in patients with thyroid eye disease
- 1 January 2018
- Published by Springer Nature
- Vol. 1074, 447-455
Valproic Acid Inhibits Human Retinal Pigment Epithelial (hRPE) Cell Proliferation Via a P38 MAPK Signaling Mechanism
Valproic acid (VPA) has been reported to inhibit cancer cell growth and has therapeutic use in retinal diseases. However, the mechanism of this action remains unclear. In order to explore this mechanism, primary human retinal pigment epithelial (hRPE) cell cultures were established. Cell viability was assessed by the trypan blue exclusion method (T), and the cell proliferation was measured by H-3-thymidine incorporation (3H-thy). P38 synthesis was quantitated by using 14C-methionine-labeled P38 (14C-P38) by using P38-specific antibody. SB203580 (SB), a selective inhibitor of p38 MAPK, was also used to test the specificity of P38 stimulation. Antinuclear staining (NS) studies were performed by DAPI. Statistical significance was established by student's t-test. We observed that VPA (1 mM) inhibited 10% fetal bovine serum (FBS)-stimulated cell proliferation (1.75 +/- 0.37 vs. 3.25 +/- 0.68 cells per 1 mu l +/- SEM, p < 0.05, n = 4). VPA also stimulated 14C-P38 synthesis in a dose-dependent manner. SB (30 mu M) inhibited VPA (4 mM)-stimulated 14C-P38 synthesis (197.74 +/- 41.17 vs. 425.89 +/- 59.17, CPM +/- SEM, p < 0.05, n = 4) and increased hRPE cell proliferation (1.79 +/- 0.45 vs. 4.93 +/- 1.12 cells per 1 mu l +/- SEM, p < 0.05, n = 4); NS demonstrated VPA-induced cell damage. We conclude that VPA inhibits hRPE cell growth via P38 MAP mechanism and may be of therapeutic value in treating or preventing proliferative eye diseases.
- 1 January 2018
- Published by Springer Nature
- Vol. 1074, 447-455
Valproic Acid Inhibits Human Retinal Pigment Epithelial (hRPE) Cell Proliferation Via a P38 MAPK Signaling Mechanism
Valproic acid (VPA) has been reported to inhibit cancer cell growth and has therapeutic use in retinal diseases. However, the mechanism of this action remains unclear. In order to explore this mechanism, primary human retinal pigment epithelial (hRPE) cell cultures were established. Cell viability was assessed by the trypan blue exclusion method (T), and the cell proliferation was measured by H-3-thymidine incorporation (3H-thy). P38 synthesis was quantitated by using 14C-methionine-labeled P38 (14C-P38) by using P38-specific antibody. SB203580 (SB), a selective inhibitor of p38 MAPK, was also used to test the specificity of P38 stimulation. Antinuclear staining (NS) studies were performed by DAPI. Statistical significance was established by student's t-test. We observed that VPA (1 mM) inhibited 10% fetal bovine serum (FBS)-stimulated cell proliferation (1.75 +/- 0.37 vs. 3.25 +/- 0.68 cells per 1 mu l +/- SEM, p < 0.05, n = 4). VPA also stimulated 14C-P38 synthesis in a dose-dependent manner. SB (30 mu M) inhibited VPA (4 mM)-stimulated 14C-P38 synthesis (197.74 +/- 41.17 vs. 425.89 +/- 59.17, CPM +/- SEM, p < 0.05, n = 4) and increased hRPE cell proliferation (1.79 +/- 0.45 vs. 4.93 +/- 1.12 cells per 1 mu l +/- SEM, p < 0.05, n = 4); NS demonstrated VPA-induced cell damage. We conclude that VPA inhibits hRPE cell growth via P38 MAP mechanism and may be of therapeutic value in treating or preventing proliferative eye diseases.
- Top Cited PapersOpen Access
- 1 December 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (12) , e1221-e1234
Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis
- 1 December 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (12) , e1221-e1234
Top Cited PapersOpen AccessGlobal causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis
- Top Cited PapersOpen Access
- 1 September 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (9) , e888-e897
Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis
- 1 September 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (9) , e888-e897
Top Cited PapersOpen AccessMagnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis
- 28 July 2016
- Published by Springer Nature
- p. 613-621
Approaches to Strabismus Reoperation
- 1 June 2016
- Published by Elsevier in Kidney International
- Vol. 89 (6) , 1192-1203
Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- 1 June 2016
- Published by Elsevier in Kidney International
- Vol. 89 (6) , 1192-1203
Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference